Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
A clinical trial designed to compare the safety and iron excretion properties of
desferoxamine (DFO) and deferitrin (GT56-252), an experimental oral iron chelator.